2018 Ischaemic Heart Disorders Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Ischaemic Heart Disorders Market

June 2018 | 70 pages | ID: 280D1F7E465EN
VPAResearch

Abstracts

Ischaemic heart disorder is a heart condition in which plaque piles up in arteries of a patient, which reduces the area for free flow of blood, thereby, causing angina or chest pain. This can eventually turn out to be a heart attack and arrhythmia. With an estimated 18 million population being affected in the US, Ischaemic heart disorders are among the most rapidly expanding disease in the US and world. Further, the US Ischaemic heart disorders market is sized at $95 billion during 2017.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Ischaemic Heart Disorders pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Ischaemic Heart Disorders pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Ischaemic Heart Disorders pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES
1.2 List of Tables

2 ISCHAEMIC HEART DISORDERS PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Ischaemic Heart Disorders Pipeline Snapshot
2.3 Ischaemic Heart Disorders Pipeline by Phase
2.4 Ischaemic Heart Disorders Pipeline by Company
2.5 Ischaemic Heart Disorders Pipeline by Mechanism of Action

3 ISCHAEMIC HEART DISORDERS- COMPANY WISE PIPELINE ANALYSIS

advanceCor GmbH
Angionetics Inc
AngioSoma Inc
APT Therapeutics Inc
Ascendia Pharmaceuticals LLC
AstraZeneca Plc
Bayer HealthCare Pharmaceuticals
Bio-Thera Solutions Ltd
Biscayne Pharmaceuticals Inc
Bracco Imaging S.p.A.
Capricor Therapeutics Inc
CardioVascular BioTherapeutics Inc
CSL Ltd
DalCor Pharmaceuticals Inc
Hemostemix Inc
Idorsia Ltd
Jaan Biotherapeutics LLC
LipimetiX Development Inc
MedImmune LLC
Pharmahungary
Proteon Therapeutics Inc
Recardio, Inc.
Resverlogix Corp
Servier Laboratories Limited
The Medicines Company
Vasade Biosciences
VESSL Therapeutics Ltd
ViroMed Co Ltd
XyloCor Therapeutics Inc
List Continues…

4 ISCHAEMIC HEART DISORDERS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ISCHAEMIC HEART DISORDERS PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Ischaemic Heart Disorders Pipeline by Phase, H2- 2018
Figure 2: Ischaemic Heart Disorders Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Ischaemic Heart Disorders Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Ischaemic Heart Disorders Pipeline by Phase, H2- 2018
Ischaemic Heart Disorders Pipeline by Companies, H2- 2018
Ischaemic Heart Disorders Pipeline by Mechanism of Action, H2- 2018
Table 1: advanceCor GmbH Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 2: Angionetics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 3: AngioSoma Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 4: APT Therapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 5: Ascendia Pharmaceuticals LLC Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 6: AstraZeneca Plc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 7: Bayer HealthCare Pharmaceuticals Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 8: Bio-Thera Solutions Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 9: Biscayne Pharmaceuticals Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 10: Bracco Imaging S.p.A. Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 11: Capricor Therapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 12: CardioVascular BioTherapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 13: CSL Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 14: DalCor Pharmaceuticals Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 15: Hemostemix Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 16: Idorsia Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 17: Jaan Biotherapeutics LLC Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 18: LipimetiX Development Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 19: MedImmune LLC Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 20: Pharmahungary Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 21: Proteon Therapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 22: Recardio, Inc. Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 23: Resverlogix Corp Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 24: Servier Laboratories Limited Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 25: The Medicines Company Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 26: Vasade Biosciences Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 27: VESSL Therapeutics Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 28: ViroMed Co Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 29: XyloCor Therapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018
Table 30: List Continues… Ischaemic Heart Disorders Pipeline Drugs, H2- 2018